ruxolitinib,Pelabresib
novartis,incyte,constellation pharmaceuticals
['#myelof', 'ruxolitinib', 'rux,(-crux),(-trux),(-deruxtecan)']
a phase 2 #clinicaltrial is underway evaluating the use of the bet inhibitor pelabresib for #myelofibrosis. presented these #research findings today at #ash22: 
The @WeillCornell Richard T. Silver Myeloproliferative Neoplasms (MPN) Center is committed to scientific research and cutting-edge care for people with MPNs.